Tamtam Try Tamtam free
Elevance Health logo

Elevance Health account plan

integrated whole health approach

At a glance

Elevance Health, an Indianapolis Blue Cross Blue Shield insurer, has about 45.2 million medical members and $197,584 million FY2025 revenue.

Elevance Health, headquartered in Indianapolis, is one of the largest U.S. health insurers by medical membership, with about 45.2 million medical members at December 31, 2025. It is the Blue Cross licensee in California and the Blue Cross and Blue Shield licensee in 13 other states, trading mainly as Anthem, and also sells under the Wellpoint, Carelon, MMM and Simply Healthcare brands. It earns risk-based premiums, administrative fees from self-funded employers, and pharmacy and health service fees through Carelon. FY2025 operating revenue was $197,584 million (+12.8%) and shareholders' net income $5,662 million (-5.3%); about 32% of revenue came from U.S. government agencies. It employed about 97,100 people at year-end 2025 (71,900 in the U.S., 25,200 international).

Business units

Strategic priorities

Lower cost and simpler navigation
The CEO restated the strategy in April 2026 as to "lower the cost of healthcare and simplify how people navigate the system", with leadership realigned to tie Health Benefits more closely to Carelon.
AI at scale
Elevance is investing more than $1 billion in digital and AI-enabled capabilities: an AI virtual assistant used by 22 million commercial members, AI access for more than 60,000 associates, and Health OS in prior authorization with a goal of 80% real-time decisions.
Operating Model Transformation Program
A 2026-2027 programme to cut organisational layers, modernise IT platforms and use AI more widely, including targeted workforce reductions; $129 million of charges were booked in H1 2026.
Fixing Medicaid and repositioning Medicare Advantage
Medicaid margin is guided at about -1.75% for 2026, seen as the trough; Elevance is exiting the D.C. Medicaid market and expects more exits over the next 12 to 18 months. Medicare Advantage is refocused on D-SNP and HMO products and on track for at least a 2% operating margin in 2026.
Scaling Carelon value-based solutions
CareBridge was combined with care-at-home into one risk-based offer; the programmes have reduced hospital readmission by 20%, and aligned medical-pharmacy clients save upwards of $100 per member per month.
Return to EPS growth in 2027
Management targets at least 12% adjusted EPS growth in 2027 off a 2026 baseline of at least $26.

Latest results

In Q2 2026 operating revenue was $49,826 million (+0.8%), with premium rate increases and CarelonRx growth offset by membership attrition. Shareholders' net income fell 16.1% to $1,463 million and diluted EPS was $6.71 (adjusted $7.45); the benefit expense ratio rose to 89.7% on elevated Medicaid and Medicare cost trend, partly offset by better Individual ACA results. Medical membership was 44,949 thousand at June 30, 2026 (-1.5%), with Medicare Advantage down 15.9% after deliberate repositioning. Full-year 2026 guidance was raised to adjusted diluted EPS of at least $27.00, diluted EPS of at least $20.10 and operating cash flow of at least $6.0 billion. CMS confirmed on July 13, 2026 that the Medicare Advantage risk-adjustment matter is closed without sanctions.

Investments and deals

Recent acquisitions
Paragon Healthcare (infusion, March 2024), CareBridge (December 10, 2024) and Centers Plan for Healthy Living (New York managed long-term care, December 31, 2024); the life and disability business was sold April 1, 2024.
Digital and AI investment
More than $1 billion in digital and AI-enabled capabilities, including Sydney Health, which touches about 22 million members, and the Health OS provider connectivity platform.
One-time second-half 2026 investments
An approximately $0.80 per share below-the-line gain in Q2 2026 is being spent on one-time investments in medical cost management, member experience, provider connectivity, operating efficiency and Carelon.
Capital returns
In 2025 Elevance spent $2,605 million on buybacks, $1,529 million on dividends and $1,116 million on capex; six-month 2026 repurchases were $1,358 million and the quarterly dividend is $1.72.
ACA market expansion
ACA expansion into Florida, Maryland and Texas in 2025 and into Washington under Wellpoint in 2026.

Challenges and risks

Elevated medical cost trend
The FY2025 benefit expense ratio rose to 90.0% on higher cost trend in all lines; Medicaid pressure comes from behavioral health including ABA therapy, specialty pharmacy, outpatient surgery and emergency department use.
Policy changes to Medicaid, ACA and PBMs
Enhanced ACA premium tax credits expired December 31, 2025; OBBBA Medicaid work requirements and redeterminations phase in mostly in 2027-2028; the 2026 PBM reform requires rebate pass-through and Part D delinking from 2028.
Membership attrition
Medicaid fell to 8.5 million members in 2025 (-4.7%), and medical membership dropped 469 thousand in Q2 2026 on a commercial fee-based customer transition and ACA and Medicaid attrition.
Government payment scrutiny
CMS is scaling up RADV audits; a CMS risk-adjustment matter led to a $935 million accrual in Q1 2026 before it was closed.
Provider friction and dependence on third parties
The company names provider relations, data and cyber risk, AI use and its reliance on CVS for core pharmacy services among its risks.

What leadership says

“Our second quarter results exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”

Gail K. Boudreaux, President and CEO · Second Quarter 2026 earnings release, July 15, 2026

“we're investing more than $1 billion in digital and AI-enabled capabilities”

Gail K. Boudreaux, President and CEO · Q1 2026 earnings call, April 22, 2026

“In many cases, we've compressed months of work into days.”

Gail K. Boudreaux, President and CEO · Q2 2026 earnings call, July 15, 2026, on medical cost management

“maniacally focused on affordability and simplicity”

Morgan Kendrick, President, Commercial · Q2 2026 earnings call, July 15, 2026, describing the commercial market

Where a supplier can help

AI and automation for administrative work
Tied to the AI-at-scale priority and the Transformation Program: Elevance wants to automate administrative expense, simplify structures and modernise IT platforms.
Provider connectivity and prior authorization
Tied to the provider-friction challenge: the goal of 80% real-time prior authorization and fewer documentation requests and avoidable denials opens room for interoperability and clinical data tools.
Medical cost management in Medicaid
Tied to the medical cost challenge: behavioral health, specialty pharmacy and emergency department use are named cost drivers where analytics or care programmes could help.
Member engagement and Stars
Tied to the Medicare Advantage repositioning: Stars is a core priority, supported by AI-powered member engagement and clinical data interoperability.
Employer affordability offers
Tied to the commercial selling season: with a near-record National Accounts pipeline and employers focused on affordability, partners that strengthen integrated medical-pharmacy offers fit the sales motion.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Elevance Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Elevance Health

What does Elevance Health do?

Elevance Health is a U.S. health insurer and Blue Cross Blue Shield licensee (mainly as Anthem) that also runs the CarelonRx pharmacy benefit manager and Carelon health services. Its companies serve approximately 104 million consumers.

What is Elevance Health's revenue?

FY2025 operating revenue was $197,584 million, up 12.8%, with shareholders' net income of $5,662 million. Q2 2026 operating revenue was $49,826 million.

How many employees does Elevance Health have?

About 97,100 at December 31, 2025: 71,900 in the U.S. and 25,200 internationally.

Who leads Elevance Health?

Gail K. Boudreaux has been President and CEO since November 2017; Mark B. Kaye is CFO.

What is Elevance Health's strategy?

To lower the cost of healthcare and simplify navigation, by tying Health Benefits closer to Carelon, using AI at scale, fixing Medicaid margins and repositioning Medicare Advantage, with a target of at least 12% adjusted EPS growth in 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)